Trial Profile
An efficacy trial of combination 123I-FP-CIT and 123I-MIBG in Parkinson syndrome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2016
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary) ; Ioflupane 123I (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 26 Sep 2016 New trial record